565 related articles for article (PubMed ID: 15269138)
1. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
3. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
5. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
7. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550
[TBL] [Abstract][Full Text] [Related]
8. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
9. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
11. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
12. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
13. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to cisplatin in cells with acquired resistance to copper.
Safaei R; Katano K; Samimi G; Naerdemann W; Stevenson JL; Rochdi M; Howell SB
Cancer Chemother Pharmacol; 2004 Mar; 53(3):239-46. PubMed ID: 14648017
[TBL] [Abstract][Full Text] [Related]
16. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines.
Kassack MU; Stratenschulte C
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):597-8. PubMed ID: 16372532
[No Abstract] [Full Text] [Related]
20. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]